Menu Search
Equities

Creo Medical Group PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert
1RC:STU

Creo Medical Group PLC

Actions
  • Price (EUR)0.197
  • Today's Change-0.001 / -0.51%
  • Shares traded0.00
  • 1 Year change-17.92%
  • Beta1.2322
Data delayed at least 15 minutes, as of Feb 10 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Creo Medical Group plc is a medical device company. The Company is focused on the development and commercialization of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy. It is engaged in the research, development and distribution of electrosurgical medical devices relating to the field of surgical endoscopy. The Company has developed the CROMA powered by Kamaptive full-spectrum adaptive technology, which provides optimized surgical capability and patient outcomes. The Kamaptive is a seamless, intuitive integration of multi-modal energy sources. Its CROMA delivers bipolar radiofrequency (RF) energy for precise localized cutting and focused high frequency microwave (MW) energy for controlled coagulation and ablation via a single accessory port. This technology, combined with its range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions.

  • Revenue in GBP (TTM)2.20m
  • Net income in GBP12.60m
  • Incorporated2016
  • Employees133.00
  • Location
    Creo Medical Group PLCUnit 2 Beaufort Park,, Beaufort Park WayCHEPSTOW NP16 5UHUnited KingdomGBR
  • Phone+44 129 160 6005
  • Websitehttps://creomedical.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.